MA40480B1 - Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie - Google Patents

Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Info

Publication number
MA40480B1
MA40480B1 MA40480A MA40480A MA40480B1 MA 40480 B1 MA40480 B1 MA 40480B1 MA 40480 A MA40480 A MA 40480A MA 40480 A MA40480 A MA 40480A MA 40480 B1 MA40480 B1 MA 40480B1
Authority
MA
Morocco
Prior art keywords
schizophrenia
sustained
crystallization
treatment
release formulations
Prior art date
Application number
MA40480A
Other languages
English (en)
Inventor
Wilfredo Morales Jr
Tarek A Zeidan
Renato A Chiarella
Steven G Wright
Jason M Perry
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MA40480B1 publication Critical patent/MA40480B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne des procédés de production d'injection retard d'aripiprazole lauroxil recristallisé dans lesquels des particules de l'aripiprazole lauroxil ont une surface d'environ 0,50 à environ 3,3 m²/g; et des cristaux d'aripiprazole lauroxil produits par de tels procédés. La présente invention concerne un procédé de fabrication d'un composé de formule (a) sous forme cristalline dans lequel ra est ch20c(o)r et dans lequel r1 est un fragment aliphatique substitué ou non substitué.
MA40480A 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie MA40480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
PCT/US2015/046525 WO2016032950A1 (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Publications (1)

Publication Number Publication Date
MA40480B1 true MA40480B1 (fr) 2021-08-31

Family

ID=55347322

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055917A MA55917A (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
MA40480A MA40480B1 (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055917A MA55917A (fr) 2014-08-25 2015-08-24 Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie

Country Status (20)

Country Link
US (5) US10064859B2 (fr)
EP (2) EP3185867B1 (fr)
JP (2) JP6591546B2 (fr)
CN (2) CN111454207B (fr)
AU (2) AU2015306910B2 (fr)
CA (1) CA2959329C (fr)
CY (1) CY1124058T1 (fr)
DK (1) DK3185867T3 (fr)
ES (2) ES2994850T3 (fr)
HR (1) HRP20210551T1 (fr)
HU (1) HUE054641T2 (fr)
IL (1) IL250661B (fr)
LT (1) LT3185867T (fr)
MA (2) MA55917A (fr)
PL (1) PL3185867T3 (fr)
PT (1) PT3185867T (fr)
RS (1) RS61709B1 (fr)
SI (1) SI3185867T1 (fr)
SM (1) SMT202100212T1 (fr)
WO (1) WO2016032950A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
SMT202100212T1 (it) * 2014-08-25 2021-07-12 Alkermes Pharma Ireland Ltd Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia
WO2016181406A1 (fr) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Procédé amélioré pour la préparation d'aripiprazole doté d'une taille de particule réduite
WO2018104953A1 (fr) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 7-{4-[4-(2,3-dichlorophényl)-pipérazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)méthyl dodécanoate
ES2903278T3 (es) 2017-07-28 2022-03-31 Interquim Sa Procedimiento para la preparación de aripiprazol lauroxil
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
CA2655335C (fr) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Posologie associee aux esters de paliperidone injectables a action prolongee
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
WO2012077134A1 (fr) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Méthode de préparation de polymorphes d'aripiprazole
AU2012204174B2 (en) * 2011-01-07 2016-07-21 Neodyne Biosciences, Inc. Wound or skin treatment devices and methods
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CA2867121C (fr) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
JP6654042B2 (ja) * 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
SMT202100212T1 (it) * 2014-08-25 2021-07-12 Alkermes Pharma Ireland Ltd Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia

Also Published As

Publication number Publication date
US11883394B2 (en) 2024-01-30
US10064859B2 (en) 2018-09-04
AU2020264303B2 (en) 2022-10-13
DK3185867T3 (da) 2021-03-15
US20210205302A1 (en) 2021-07-08
SMT202100212T1 (it) 2021-07-12
NZ729479A (en) 2021-03-26
PL3185867T3 (pl) 2021-11-22
EP3185867A1 (fr) 2017-07-05
HUE054641T2 (hu) 2021-09-28
HRP20210551T1 (hr) 2021-08-20
JP6591546B2 (ja) 2019-10-16
AU2015306910A8 (en) 2020-11-19
US20160051546A1 (en) 2016-02-25
IL250661B (en) 2020-04-30
CA2959329A1 (fr) 2016-03-03
JP2019210296A (ja) 2019-12-12
LT3185867T (lt) 2021-06-10
AU2015306910A1 (en) 2017-03-16
EP3865476B1 (fr) 2024-08-14
IL250661A0 (en) 2017-04-30
PT3185867T (pt) 2021-04-12
JP2017526747A (ja) 2017-09-14
US10973816B2 (en) 2021-04-13
EP3185867B1 (fr) 2021-01-13
CN111454207B (zh) 2024-10-18
ES2994850T3 (en) 2025-02-03
CN107106556B (zh) 2020-06-05
CY1124058T1 (el) 2022-05-27
SI3185867T1 (sl) 2021-08-31
CN107106556A (zh) 2017-08-29
US20190015408A1 (en) 2019-01-17
WO2016032950A1 (fr) 2016-03-03
ES2862098T3 (es) 2021-10-07
US20240245676A1 (en) 2024-07-25
MA55917A (fr) 2022-03-16
AU2015306910B2 (en) 2020-11-19
US10478434B2 (en) 2019-11-19
EP3185867A4 (fr) 2018-01-24
US20200108063A1 (en) 2020-04-09
EP3865476A1 (fr) 2021-08-18
CA2959329C (fr) 2023-06-27
AU2020264303A1 (en) 2020-11-26
RS61709B1 (sr) 2021-05-31
CN111454207A (zh) 2020-07-28

Similar Documents

Publication Publication Date Title
CY1124058T1 (el) Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
EP3865461A4 (fr) Procédé de traitement des eaux usées de production provenant de la préparation d'oxyde de propylène par procédé de co-oxydation
JP2020511461A5 (fr)
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
MX374296B (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas
MX380516B (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA48798B1 (fr) Procédé de production d'ozanimod
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
CU20210007A7 (es) Derivados de aril-n-arilo para el tratamiento de una infección por virus de ácido ribonucleico (arn)
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
MX2021000089A (es) Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn).
JP2016529315A5 (fr)
MA39205A1 (fr) Polymères contenant des amines primaires utiles en tant qu'inhibiteurs de tartre
EP3792269A4 (fr) Procédé de production de composé d'acide oligonucléique
MX2019008116A (es) Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos.
EA202192760A1 (ru) Трициклические соединения
JP2019523279A5 (fr)
PH12021551495A1 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
EA201891095A1 (ru) Альфа-сложные аминоэфиры производного гидроксипропилтиазолидин карбоксамида и его солевая форма, кристаллический полиморф
RU2007136782A (ru) Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины